Painting by the numbers, Sana founders carve up a giant unicorn-sized IPO — for a biotech that hasn’t quite made it to the clinic – Endpoints News
In August 2018, a tiny biotech spinout from Cornell announced that it had hired former senior Pfizer executive Geno Germano as CEO. And then they didn’t say anything else. For two years. The company, called Elucida Oncology, literally didn’t issue another press release until last October when it hired a chief medical officer.
Now, however, Elucida appears ready to take the lid off her surgeries. On Tuesday, JPano guided investors at JP Morgan through the nanoparticle technology they were developing for cancer. On the same day, the company announced new funding and raised $ 44 million in an “A-1” series to bring to the clinic this year.
Continue reading Endpoints with a Free Subscription
Unlock this story instantly and join over 97,600 biopharma professionals who read endpoints every day – for free.